RESUMO
BACKGROUND: The independent predictive value of d-dimer and inflammatory markers for the risk of recurrent adverse events in patients with acute chest pain but normal levels of cardiac troponin I (cTnI) remains unclear. METHODS: We studied 391 patients admitted to the hospital in 1 year with acute ischemic-type chest pain. Creatine kinase-myocardial band isoenzyme (CK-MB) mass and cTnI levels were measured in initial and 12-hour samples. Soluble intercellular adhesion molecule (sICAM)-1, vascular cell adhesion molecule (sVCAM)-1, sP-selectin, sE-selectin, high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL6), fibrinogen, and d-dimer levels were measured in initial samples. A 1-year incidence of death, myocardial infarction (MI), revascularization, or readmission with chest pain was determined (with death/MI as the primary end point). RESULTS: Patients with normal levels of CK-MB(mass) and cTnI (195/391[50%]) were at a lower risk than patients with elevated levels of CK-MB(mass) or cTnI, but still had an important incidence of events (77/195[39%]). Marker elevation was defined as >75th percentile (upper quartile). Elevated d-dimer levels (>580 ng/mL) was predictive of death/MI (odds ratio, 5.4; 95% CI, 1.5-20.2; P =.005). Elevated sP-selectin levels (>152 ng/mL; odds ratio, 3.2; 95% CI, 0.9-11.6; P =.06) trended to increased death/MI rates, with weaker trends for elevated levels of hsCRP (>7.1 mg/L), IL6 (>10.7 pg/mL), and ST depression. Other markers, other electrocardiogram changes, or classic risk factors were not predictive of death/MI. With a multivariate analysis, d-dimer and sP-selectin were found to be of independent significance for death/MI after adjustment for inflammatory, hemostatic, and electrocardiogram markers and d-dimer after adjustment for classic risk factors. CONCLUSION: Normal cTnI levels after acute chest pain does not confer absence of future risk. Concurrent assessment of d-dimer and inflammatory markers may improve risk stratification.
Assuntos
Biomarcadores/sangue , Isquemia Miocárdica/sangue , Análise de Variância , Proteína C-Reativa/análise , Creatina Quinase/sangue , Creatina Quinase Forma MB , Selectina E/sangue , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Humanos , Isoenzimas/sangue , Infarto do Miocárdio/sangue , Infarto do Miocárdio/mortalidade , Razão de Chances , Selectina-P/sangue , Recidiva , Medição de Risco , Troponina I/sangue , Troponina T , Molécula 1 de Adesão de Célula Vascular/sangueRESUMO
BACKGROUND: Measurement of glucose in multiple Field Laboratories requires rigorous standardization when patients and caregivers are masked, unless predefined thresholds are met. Local misclassification of participants at the thresholds can introduce recruitment bias and adversely affect the integrity of study findings. PURPOSE: To describe the challenges and the approach to meeting them in measuring glucose, HbA1c, and C-peptide in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. HAPO is an observational epidemiologic study of 25 000 pregnant women from 15 centres in 10 countries, designed to clarify unanswered questions on associations of maternal glycemia, less severe than overt diabetes mellitus, with risks of adverse pregnancy outcome. METHODS: Glucose tolerance (75 g two-hour OGTT) is assessed locally at 24-32 weeks' gestation, with results masked if fasting and two-hour plasma glucose are =5.8 mmol/L and =11.1 mmol/L, respectively. For analysis of outcomes HAPO utilizes measurements of glucose, C-peptide, and HbA1c on frozen samples in a Central Laboratory; measurement of HbA1c on stored, frozen blood also creates special challenges. A common external quality assessment scheme was used to standardize glucose measurements between Field Centre and Central Laboratories before and during data collection. RESULTS: Agreement between Field Centres and the Central Laboratory in rates above the masking thresholds has been excellent (Kappa = 0.79, P < 0.001), with rates of 1.8 and 1.7% respectively. Percent technical error for Central Laboratory OGTT measurements of glucose, C-peptide, and HbA1c, were 2.0, 4.2, and 2.0, respectively. LIMITATIONS: It is not possible to assess if comparable results could have been obtained with a less rigorous approach to standardization. CONCLUSIONS: HAPO has been successful in ensuring comparability of glucose measurement between its Central Laboratory and Field Centre laboratories and in measuring its key metabolites with accuracy and precision. Recruitment bias based on glucose measurement has been avoided.